GlobeNewswire Inc | Sep 14, 2020 01:00AM EDT

September 14, 2020



FDA grants Dupixent (dupilumab) Breakthrough Therapy designation for eosinophilic esophagitis

-- Designation based on positive results from Part A of pivotal Phase 3 trial -- Dupixent is the first and only biologic to show positive and clinically-meaningful Phase 3 results in patients 12 years and older with eosinophilic esophagitis (EoE) -- There are currently no FDA-approved treatments for this chronic type 2 inflammatory disease that damages the esophagus and impacts patients ability to swallow and eat -- Designation supports Dupixents potential in another disease driven by type 2 inflammation

PARIS and TARRYTOWN, N.Y., September 14, 2020 The U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to Dupixent (dupilumab) for the treatment of patients 12 years and older with eosinophilic esophagitis (EoE). The designation for this investigational use is based on positive results from Part A of a Phase 3 trial in patients with EoE.

There are currently no FDA-approved medicines for EoE, a chronic and progressive type 2 inflammatory disease that damages the esophagus and prevents it from working properly. Over time, excessive type 2 inflammation causes scarring and narrowing of the esophagus, making it difficult to swallow. If left untreated, EoE can affect a patients ability to eat and cause food to become stuck after being swallowed (food impaction), which can lead to a medical emergency.

In the U.S. alone, there are approximately 160,000 patients with EoE who are currently being treated with various unapproved therapies or diet modification. Of these patients, approximately 50,000 have failed multiple treatments.

Sanofi and Regeneron previously reported positive results from Part A of the pivotal Phase 3 trial evaluating Dupixent in patients 12 years and older with EoE. Part A of the randomized, double-blind, placebo-controlled trial of 81 patients met both of its co-primary endpoints, as well as all key secondary endpoints. Patients treated weekly with Dupixent 300 mg over a 24-week treatment period experienced a reduction in symptoms, esophageal inflammation and abnormal endoscopic findings in the esophagus.

Part A of the trial also demonstrated safety results consistent with the known safety profile of Dupixent in its approved indications. The EoE trial is ongoing, with additional patients enrolling in Part B as well as patients continuing in a 28-week extended active treatment period (Part C) after completing either Part A or Part B.

Breakthrough Therapy designation is designed to expedite the development and review of drugs in the U.S. that target serious or life-threatening conditions. Drugs qualifying for this designation must show preliminary clinical evidence that the drug may demonstrate a substantial improvement on clinically significant endpoints over available therapies, or over placebo if there are no available therapies. In 2017, Dupixent also was granted Orphan Drug designation for the potential treatment of EoE. This is given to investigational medicines intended for the treatment of rare diseases that affect fewer than 200,000 people in the U.S.

The potential use of Dupixent in eosinophilic esophagitis is currently under clinical development, and its safety and efficacy for this indication have not been evaluated by any regulatory authority.

About Dupixent

Dupixent is approved in the U.S. to treat patients aged 6 years and older with moderate-to-severe atopic dermatitis that is not well controlled with prescription therapies used on the skin (topical), or who cannot use topical therapies; for use with other asthma medicines for the maintenance treatment of moderate-to-severe eosinophilic or oral steroid dependent asthma in patients aged 12 years and older whose asthma is not controlled with their current asthma medicines; and for use with other medicines for the maintenance treatment of chronic rhinosinusitis with nasal polyposis (CRSwNP) in adults whose disease is not controlled. In adolescents 12 years of age or older, it is recommended that Dupixent be administered by or under the supervision of an adult. In children younger than 12 years of age, Dupixent should be administered by a caregiver.

Outside of the U.S., Dupixent is approved for specific patients with moderate-to-severe atopic dermatitis and certain patients with asthma in a number of other countries around the world, including the EU and Japan. Dupixent is also approved in the EU and Japan to treat certain adults with severe CRSwNP.

Dupixent is a fully-human monoclonal antibody that inhibits the signaling of the interleukin-4 (IL-4) and interleukin-13 (IL-13) proteins. Data from Dupixent clinical trials have shown that IL-4 and IL-13 are key drivers of the type 2 inflammation that plays a major role in asthma, CRSwNP and atopic dermatitis.

Dupilumab Development Program

To date, dupilumab has been studied in more than 10,000 patients across 50 clinical trials in various chronic diseases driven by type 2 inflammation. In addition to the currently approved indications, Sanofi and Regeneron are studying dupilumab in a broad range of diseases driven by type 2 inflammation or other allergic processes, including pediatric asthma (6 to 11 years of age, Phase 3), pediatric atopic dermatitis (6 months to 5 years of age, Phase 3), eosinophilic esophagitis (Phase 3), chronic obstructive pulmonary disease (Phase 3), bullous pemphigoid (Phase 3), prurigo nodularis (Phase 3), chronic spontaneous urticaria (Phase 3), and food and environmental allergies (Phase 2). These potential uses are investigational, and the safety and efficacy of dupilumab in these conditions have not been evaluated by any regulatory authority. Dupilumab is being jointly developed by Regeneron and Sanofi under a global collaboration agreement.

About Regeneron

Regeneron (NASDAQ: REGN) is a leading biotechnology company that invents life-transforming medicines for people with serious diseases. Founded and led for over 30 years by physician-scientists, our unique ability to repeatedly and consistently translate science into medicine has led to seven FDA-approved treatments and numerous product candidates in development, all of which were homegrown in our laboratories. Our medicines and pipeline are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, pain, infectious diseases and rare diseases.

Regeneron is accelerating and improving the traditional drug development process through our proprietary VelociSuite technologies, such as VelocImmune, which uses unique genetically-humanized mice to produce optimized fully-human antibodies and bispecific antibodies, and through ambitious research initiatives such as the Regeneron Genetics Center, which is conducting one of the largest genetics sequencing efforts in the world. For additional information about the company, please visit www.regeneron.com or follow @Regeneron on Twitter.



About Sanofi

Sanofi is dedicated to supporting people through their health challenges. Weare a global biopharmaceutical company focused on human health. We preventillness with vaccines, provide innovative treatments to fight pain and easesuffering. We stand by the few who suffer from rare diseases and the millionswith long-term chronic conditions.

With more than 100,000 people in 100 countries, Sanofi is transformingscientific innovation into healthcare solutions around the globe.

Sanofi, Empowering Life

Sanofi Investor Relations ? Contacts Paris Eva Schaefer-Jansen Arnaud Delepine Yvonne Naughton



Sanofi Investor Relations ? Contacts NorthSanofi Media Relations Contact AmericaSally Bain Felix LauscherTel.: +1 (781) 264-1091 Fara BerkowitzSally.Bain@sanofi.com Suzanne Greco



Sanofi IR main line: Tel.: +33 (0)1 53 77 45 45 ir@sanofi.com https://www.sanofi.com/en/investors/contact





Regeneron Media Relations Contact Regeneron Investor Relations ContactSharon Chen Mark HudsonTel: +1 (914) 847-1546 Tel: +1 (914) 847-3482Sharon.Chen@regeneron.com Mark.Hudson@regeneron.com

Sanofi Forward-Looking StatementsThis press release contains forward-looking statements as defined in thePrivate Securities Litigation Reform Act of 1995, as amended. Forward-lookingstatements are statements that are not historical facts. These statementsinclude projections and estimates regarding the marketing and other potentialof the product, or regarding potential future revenues from the product.Forward-looking statements are generally identified by the words ?expects?,?anticipates?, ?believes?, ?intends?, ?estimates?, ?plans? and similarexpressions. Although Sanofi?s management believes that the expectationsreflected in such forward-looking statements are reasonable, investors arecautioned that forward-looking information and statements are subject tovarious risks and uncertainties, many of which are difficult to predict andgenerally beyond the control of Sanofi, that could cause actual results anddevelopments to differ materially from those expressed in, or implied orprojected by, the forward-looking information and statements. These risks anduncertainties include among other things, unexpected regulatory actions ordelays, or government regulation generally, that could affect the availabilityor commercial potential of the product, the fact that product may not becommercially successful, the uncertainties inherent in research anddevelopment, including future clinical data and analysis of existing clinicaldata relating to the product, including post marketing, unexpected safety,quality or manufacturing issues, competition in general, risks associated withintellectual property and any related future litigation and the ultimateoutcome of such litigation, and volatile economic and market conditions, andthe impact that COVID-19 will have on us, our customers, suppliers, vendors,and other business partners, and the financial condition of any one of them, aswell as on our employees and on the global economy as a whole. Any materialeffect of COVID-19 on any of the foregoing could also adversely impact us. Thissituation is changing rapidly and additional impacts may arise of which we arenot currently aware and may exacerbate other previously identified risks. Therisks and uncertainties also include the uncertainties discussed or identifiedin the public filings with the SEC and the AMF made by Sanofi, including thoselisted under ?Risk Factors? and ?Cautionary Statement Regarding Forward-LookingStatements? in Sanofi?s annual report on Form 20-F for the year ended December31, 2019. Other than as required by applicable law, Sanofi does not undertakeany obligation to update or revise any forward-looking information orstatements.

Regeneron Forward-Looking Statements and Use of Digital Media

This press release includes forward-looking statements that involve risks anduncertainties relating to future events and the future performance of RegeneronPharmaceuticals, Inc. (?Regeneron? or the ?Company?), and actual events orresults may differ materially from these forward-looking statements. Words suchas ?anticipate,? ?expect,? ?intend,? ?plan,? ?believe,? ?seek,? ?estimate,?variations of such words, and similar expressions are intended to identify suchforward-looking statements, although not all forward-looking statements containthese identifying words. These statements concern, and these risks anduncertainties include, among others, the impact of SARS-CoV-2 (the virus thathas caused the COVID-19 pandemic) on Regeneron?s business and its employees,collaborators, and suppliers and other third parties on which Regeneron relies,Regeneron?s and its collaborators? ability to continue to conduct research andclinical programs, Regeneron?s ability to manage its supply chain, net productsales of products marketed by Regeneron and/or its collaborators (collectively,?Regeneron?s Products?), and the global economy; the nature, timing, andpossible success and therapeutic applications of Regeneron?s Products andRegeneron?s product candidates and research and clinical programs now underwayor planned, including without limitation Dupixent (dupilumab) for thetreatment of patients 12 years and older with eosinophilic esophagitis; thelikelihood, timing, and scope of possible regulatory approval and commerciallaunch of Regeneron?s product candidates and new indications for Regeneron?sProducts, such as dupilumab for the treatment of eosinophilic esophagitis,pediatric asthma, pediatric atopic dermatitis, chronic obstructive pulmonarydisease, bullous pemphigoid, prurigo nodularis, chronic spontaneous urticaria,food and environmental allergies, and other potential indications; the impact(if any) of the Breakthrough Therapy designation status granted to Dupixent forthe treatment of patients 12 years and older with eosinophilic esophagitis bythe U.S. Food and Drug Administration (the ?FDA?) on whether Dupixent willreceive FDA approval in this indication and the timing of such potentialapproval; uncertainty of market acceptance and commercial success ofRegeneron?s Products and product candidates and the impact of studies (whetherconducted by Regeneron or others and whether mandated or voluntary) on thecommercial success of Regeneron's Products (such as Dupixent) and productcandidates; safety issues resulting from the administration of Regeneron?sProducts (such as Dupixent) and product candidates in patients, includingserious complications or side effects in connection with the use of Regeneron?sProducts and product candidates in clinical trials; determinations byregulatory and administrative governmental authorities which may delay orrestrict Regeneron?s ability to continue to develop or commercializeRegeneron?s Products and product candidates; ongoing regulatory obligations andoversight impacting Regeneron?s Products, research and clinical programs, andbusiness, including those relating to patient privacy; the availability andextent of reimbursement of Regeneron?s Products from third-party payers,including private payer healthcare and insurance programs, health maintenanceorganizations, pharmacy benefit management companies, and government programssuch as Medicare and Medicaid; coverage and reimbursement determinations bysuch payers and new policies and procedures adopted by such payers; competingdrugs and product candidates that may be superior to, or more cost effectivethan, Regeneron?s Products and product candidates; the extent to which theresults from the research and development programs conducted by Regeneron and/or its collaborators may be replicated in other studies and/or lead toadvancement of product candidates to clinical trials, therapeutic applications,or regulatory approval; the ability of Regeneron to manufacture and managesupply chains for multiple products and product candidates; the ability ofRegeneron?s collaborators, suppliers, or other third parties (as applicable) toperform manufacturing, filling, finishing, packaging, labeling, distribution,and other steps related to Regeneron?s Products and product candidates;unanticipated expenses; the costs of developing, producing, and sellingproducts; the ability of Regeneron to meet any of its financial projections orguidance and changes to the assumptions underlying those projections orguidance; the potential for any license or collaboration agreement, includingRegeneron's agreements with Sanofi, Bayer, and Teva Pharmaceutical IndustriesLtd. (or their respective affiliated companies, as applicable), to be cancelledor terminated without any further product success; and risks associated withintellectual property of other parties and pending or future litigationrelating thereto (including without limitation the patent litigation and otherrelated proceedings relating to EYLEA^ (aflibercept) Injection, Dupixent, andPraluent^ (alirocumab)), other litigation and other proceedings and governmentinvestigations relating to the Company and/or its operations, the ultimateoutcome of any such proceedings and investigations, and the impact any of theforegoing may have on Regeneron's business, prospects, operating results, andfinancial condition. A more complete description of these and other materialrisks can be found in Regeneron?s filings with the U.S. Securities and ExchangeCommission, including its Form 10-K for the year ended December 31, 2019 andits Form 10-Q for the quarterly period ended June 30, 2020. Anyforward-looking statements are made based on management?s current beliefs andjudgment, and the reader is cautioned not to rely on any forward-lookingstatements made by Regeneron. Regeneron does not undertake any obligation toupdate publicly any forward-looking statement, including without limitation anyfinancial projection or guidance, whether as a result of new information,future events, or otherwise.

Regeneron uses its media and investor relations website and social mediaoutlets to publish important information about the Company, includinginformation that may be deemed material to investors. Financial and otherinformation about Regeneron is routinely posted and is accessible onRegeneron's media and investor relations website ( http://newsroom.regeneron.com) and its Twitter feed ( http://twitter.com/regeneron).

Attachment

-- Press Release